ArQule (ARQL) Lifted to Outperform at Leerink Swann

Leerink Swann upgraded shares of ArQule (NASDAQ:ARQL) from a market perform rating to an outperform rating in a research note released on Thursday, Marketbeat.com reports.

Several other analysts have also issued reports on the stock. Needham & Company LLC upgraded shares of ArQule from a hold rating to a buy rating in a research report on Thursday, December 14th. Zacks Investment Research lowered shares of ArQule from a buy rating to a hold rating in a research report on Wednesday, March 21st. Roth Capital initiated coverage on shares of ArQule in a research report on Thursday, February 22nd. They issued a buy rating and a $5.00 target price on the stock. B. Riley initiated coverage on shares of ArQule in a research report on Friday, February 2nd. They issued a buy rating and a $3.00 target price on the stock. Finally, ValuEngine upgraded shares of ArQule from a sell rating to a hold rating in a research report on Thursday, March 15th. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $4.08.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ ARQL traded down $0.08 during trading hours on Thursday, hitting $2.87. 1,177,721 shares of the stock were exchanged, compared to its average volume of 591,928. The company has a current ratio of 4.98, a quick ratio of 4.98 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $256.10, a price-to-earnings ratio of -7.56 and a beta of 0.83. ArQule has a 1-year low of $0.92 and a 1-year high of $3.35.

ArQule (NASDAQ:ARQL) last posted its quarterly earnings results on Monday, March 5th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.09). During the same quarter last year, the business posted ($0.10) EPS. equities research analysts forecast that ArQule will post -0.31 earnings per share for the current year.

A number of institutional investors have recently modified their holdings of ARQL. Millennium Management LLC acquired a new stake in ArQule in the fourth quarter valued at approximately $165,000. Northern Trust Corp boosted its position in ArQule by 0.9% in the second quarter. Northern Trust Corp now owns 154,513 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 1,385 shares in the last quarter. Virtu Financial LLC boosted its position in ArQule by 343.8% in the fourth quarter. Virtu Financial LLC now owns 129,038 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 99,964 shares in the last quarter. Deutsche Bank AG acquired a new stake in ArQule in the fourth quarter valued at approximately $390,000. Finally, Point72 Asset Management L.P. acquired a new stake in ArQule in the third quarter valued at approximately $2,220,000. Hedge funds and other institutional investors own 67.08% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3335986/arqule-arql-lifted-to-outperform-at-leerink-swann.html.

About ArQule

ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. Its lead product candidate is tivantinib (ARQ 197), a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer.

Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Pabyosi Coin  Trading 10% Higher  This Week
Pabyosi Coin Trading 10% Higher This Week
Bolenum 24 Hour Volume Hits $177.00
Bolenum 24 Hour Volume Hits $177.00
Polaris Industries  Given Consensus Recommendation of “Hold” by Brokerages
Polaris Industries Given Consensus Recommendation of “Hold” by Brokerages
Viper Energy Partners  Given Consensus Recommendation of “Buy” by Brokerages
Viper Energy Partners Given Consensus Recommendation of “Buy” by Brokerages
Deckers Outdoor Co.  Expected to Announce Quarterly Sales of $377.25 Million
Deckers Outdoor Co. Expected to Announce Quarterly Sales of $377.25 Million
TimkenSteel  Expected to Announce Quarterly Sales of $372.53 Million
TimkenSteel Expected to Announce Quarterly Sales of $372.53 Million


© 2006-2018 Ticker Report. Google+.